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Abstract: 
 
Fc receptors for IgG (FcγR) are widely expressed in the hematopoietic system and mediate a 
variety of inflammatory responses. There are two functional classes of FcγR, activation and 
inhibitory receptors. Since IgG immune complexes (IgG IC) bind each class with similar affinity, 
co-expression of these receptors leads to their co-ligation. Thus, expression levels of this 
antagonistic pair play a critical role in determining the cellular response. Murine mast cells co-
express the activation receptor FcγRIII and the inhibitory receptor FcγRIIb and can be activated 
by IgG IC. Mast cell activation contributes to allergic and other inflammatory diseases—
particularly those in which IgG IC may play important roles. Using mouse bone marrow-derived 
mast cells, we report that IL-4 selectively increases FcγRIII expression without altering FcγRIIb. 
This enhanced expression could be induced by Stat6 activation alone, and appeared to be 
mediated in part by increased FcγRIIIα protein synthesis without significant changes in 
transcription. The increase in FcγRIII expression was functionally significant, as it was matched 
by enhanced FcγR-mediated degranulation and cytokine production. Selective regulation of mast 
cell FcγR by interleukin-4 could alter inflammatory IgG responses and subsequently disease 
severity and progression. 
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Article: 
 
1. Introduction 
 
Mast cells have long been appreciated as effector cells in allergy and asthma. Recently, their role 
in inflammation has diversified, as mast cells are now implicated in a variety of inflammatory 
processes including host resistance to bacterial infections [1], mouse models of multiple 
sclerosis[2], rheumatoid arthritis [3], and inflammation in cardiovascular disease [4]. Mast cell 
responses are characterized by the production of vasoactive mediators, proteases, lipid-derived 
factors, and cytokines [5]. The high affinity receptor for IgE, FcεRI, is the most thoroughly 
studied mediator of mast cell function. However, recent studies have emphasized the importance 
of the IgG Fc receptors FcγRIIb and FcγRIII [6], [7], [8], [9], [10]. 
 
Murine FcγR are widely expressed in the hematopoietic system. These receptors fall into two 
distinct classes: activation and inhibitory receptors. Activation receptors include the high affinity 
FcγRI, and the low affinity FcγRIII. Aggregation of FcγRI or FcγRIII can mediate a variety of 
inflammatory processes, including degranulation, phagocytosis, antibody-dependent cellular 
cytoxicity, cytokine production, and release of inflammatory arachidonic acid 
metabolites [11], [12]. Signal transduction through these receptors is mediated by 
immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic domains of the Fc 
receptor γ chain, through recruitment and activation of tyrosine kinases such as lyn and 
syk [11], [12]. 
 
In contrast to the activation receptors, murine FcγRIIb mediates inhibitory IgG signaling. While 
ITAM sequences elicit pro-inflammatory FcγR signaling, FcγRIIb possesses immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs) that preferentially interact with tyrosine and inositol 
phosphatases. Crosslinkage of FcγRIIb with an activation receptor such as the B cell receptor, T 
cell receptor, FcεRI, FcγRI, or FcγRIII can inhibit pro-inflammatory signaling [13], [14], [15]. 
The contrasting functions of FcγRIIb and FcγRIII, together with their shared ligand binding and 
co-expression on monocytes, macrophages, neutrophils, and mast cells, allow control of IgG-
mediated signaling. Mice deficient in FcγRIIb have been used to demonstrate the importance of 
balancing this dual expression. These animals are prone to developing autoimmune conditions 
such as collagen-induced arthritis and Goodpasture’s syndrome [11], [12]. It appears that the 
activation and inhibitory Fcγ receptors have evolved as a paired antagonistic signaling system, 
allowing changes in expression levels to alter the stimulus transduced by IgG immune 
complexes. 
 
Murine mast cells express both FcγRIIb and FcγRIII [12]. While FcγRIIb is a single chain 
transmembrane protein, FcγRIII is expressed as either a trimeric complex, via association with 
paired FcεRIγ subunits, or a tetrameric complex, through association with FcεRIβ and γ subunits. 
γ subunit association is required for FcγRIII expression and signaling. In contrast, β chain 
amplifies FcγRIII signaling, but is not obligatory for expression [16]. The balance between 
FcγRIIb and FcγRIII expression on mast cells, is critical in determining the mast cell response to 
IgG complexes, as recently demonstrated using a mouse model of multiple sclerosis. Mast cell 
deficient mice reconstituted with FcγRIII−/− mast cells greatly reduced disease severity 
compared to mice reconstituted with wild type mast cells. In contrast, reconstitution with 
FcγRIIb−/− mast cells severely augmented disease pathology [17]. 
 
Mast cell-mediated inflammation is most frequently studied in the context of T helper cell type 2 
(Th2) immunity. Interleukin-4 (IL-4) is a Th2 cytokine that is critical in controlling allergic 
responses. Best known for inducing Th2 development and B cell isotype switching to IgE, IL-4 
is also a mast cell growth factor and has been shown to induce FcεRI expression on in vitro-
cultured human mast cells [18], [19], [20]. Due to these activities, IL-4 is associated with the 
pro-inflammatory effects of the Th2 response. Our studies of IL-4 have led to a more balanced 
view of its role in inflammation. We recently demonstrated that IL-4 inhibits mast cell FcεRI and 
Kit expression and signaling. Further, IL-4 was found to combine with IL-10 to induce mast cell 
death [21], [22], [23]. It appears that IL-4 may initially enhance inflammatory responses, but 
balance these effects with a delayed inhibition of mast cell function and survival, thus arguing 
for IL-4-mediated homeostasis in the Th2 response. These studies prompted us to explore IL-4 
effects on the balance of mast cell FcγRIIb/RIII expression and function. Given their identical 
ligand binding properties and co-expression on mast cells, altering the ratio of these surface 
receptors could greatly affect mast cell function and consequently, inflammatory disease. 
 
2. Results and discussion 
 
2.1. IL-4 selectively enhances FcγRIII expression 
 
To assess the effects of IL-4 on FcγRIIb and FcγRIII expression, we cultured BMMC1 in IL-3 
alone or IL-3 + IL-4. After 3 days of culture, there was a slight increase in FcγR expression as 
assessed by flow cytometry with FITC-2.4G2, an antibody that recognizes both FcγRIIb and 
FcγRIII (Fig. 1A). To determine if this increase in FcγR expression was due to an increase in 
FcγRIIb, these BMMC were stained with K9.361, an antibody specific for FcγRIIb. No change 
in FcγRIIb expression was detected after the addition of IL-4 in culture for 3 days as compared 
to cells cultured in IL-3 alone (Fig. 1B). This led us to explore the possibility that IL-4 
upregulated FcγRIII surface expression without altering FcγRIIb expression. In order to test this 
directly, we harvested BMMC from FcRγ−/−mice that lack FcγRIII but express FcγRIIb, and 
from Fcγ−/− mice that lack FcγRIIb but express FcγRIII [9], [24]. In concordance with K9.361 
staining, the addition of IL-4 did not significantly alter FcγRIIb surface expression. In contrast, 
culture in IL-3 + IL-4 consistently increased FcγRIII surface expression more than 2-fold over 
BMMC cultured in IL-3 alone (Fig. 1C). Because BMMC basal surface levels of FcγRIIb is 
greater than FcγRIII expression [25], an IL-4-mediated increase in FcγRIII could be expected to 
yield only a slight increase in staining total FcγR expression, consistent with the data shown 
in Fig. 1A. 
 
IL-4 elevated FcγRIII expression from days 2 through at least day 14 of culture. This effect 
required a minimum of 1 ng/ml of IL-4, with maximal effects at 10 ng/ml. FcγRIIb expression 
showed little or no change during this culture period (Figs. 2A and B). Thus, IL-4 selectively 
enhanced mast cell FcγRIII surface expression without significantly altering the expression of 
FcγRIIb for up to 14 days. 
 
2.2. IL-4 modestly alters FcγRIIIα mRNA expression and upregulates protein expression 
 
We investigated the mechanism of IL-4-mediated FcγRIII regulation by first assessing FcγRIIIα 
mRNA changes through RNase protection assay (RPA) analysis. The addition of IL-4 to BMMC 
cultured in IL-3 for 30 min to 72 h did not significantly alter FcγRIIIα mRNA expression, though 
a moderate increase was noted after 96 h of culture (Figs. 3A and B). This finding corroborates a 
related study in which we found that IL-4 downregulates FcεRI surface expression without 
significantly altering mRNA expression of FcεRI subunits, including the FcεRIγ chain known to 
pair with FcγRIII (Gillespie et al., submitted). Since IL-4 increased surface FcγRIII by day 2, 
and mRNA levels do not increase until day 4, it did not appear that IL-4 regulates FcγRIII 
expression via transcriptional control of the FcγRIIIα or FcεRIγ chains. 
 
 
Fig. 1. IL-4 selectively enhances FcγRIII expression. BMMC derived from wild mice were cultured in IL-3 or IL-
3 + IL-4 for three days and assessed for FcγR expression by flow cytometry with (A) anti-FcγRII/FcγRIII antibody 
(2.4G2) or (B) anti-FcγRII antibody (K9.361). (C) BMMC derived from FcRγ−/− (top) or FcγRIIb−/− (bottom) mice 
were cultured in IL-3 or IL-3 + IL-4 for 3 days and assessed for FcγR expression by flow cytometry using FITC-
2.4G2. Data shown are from at least seven independent experiments using 12 different cell populations. *p<0.05 as 
determined by analysis of variance (ANOVA) and least significant difference (LSD) analysis. 
 
 
Fig. 2. Kinetics of IL-4-mediated FcγR regulation. (A) BMMC derived from FcRγ−/−or FcγRIIb−/− mice were 
cultured in IL-3 or IL-3 + IL-4. FcγR expression was assessed by flow cytometry on the indicated days by FITC-
2.4G2 staining. Percent enhancement and standard error measurements were calculated by comparing mean 
fluorescence intensities of IL-3 + IL-4 treated BMMC to the same cells cultured in IL-3. Data shown are from nine 
independent BMMC populations analyzed in at least six separate experiments. ∗p<0.05 as determined by ANOVA 
and LSD analysis. (B) BMMC derived from FcγRIIb−/− mice were cultured in IL-3 or IL-3 with increasing 
concentrations of IL-4. Percent enhancement was calculated by comparing the mean fluorescence of cells cultured in 
IL-3 + IL-4 to cells cultured in IL-3. ∗p<0.05 as determined by ANOVA and LSD analysis. 
 
There are several post-transcriptional mechanisms by which IL-4 could increase FcγRIII surface 
expression, including increased protein synthesis, increased protein stability, and enhanced 
protein trafficking from preformed intracellular pools. To determine if the changes in FcγRIII 
surface expression were matched by an increase in total FcγRIIIα protein levels, we employed 
2.4G2 staining of fixed and permeabilized FcγRIIb-deficient BMMC. This technique, modeled 
after intracellular staining of cytokines, allowed detection of both surface and intracellular 
FcγRIIIα, since unlabelled 2.4G2 antibody added prior to fixation could block surface but not 
intracellular FITC-2.4G2 staining (data not shown). These experiments demonstrated an IL-4-
mediated increase in total FcγRIIIα protein expression that resembled the enhanced surface 
expression (Fig. 4A). 
 
 
Fig. 3. IL-4 increases FcγRIIIα mRNA protein synthesis with minimal effects on transcription. (A) Wild type 
BMMC were stimulated for 4 days with the indicated cytokines, and total RNA was subjected to RPA analysis as 
described in Materials and methods. Data shown are a representative BMMC population harvested after 4 days of 
culture, the only time point that showed any change in FcγRIIIα mRNA expression. (B) Summary of percent change 
in FcγRIIIα mRNA in cells cultured in IL-3 + IL-4, as compared to cells cultured in IL-3 alone. Phosphorimaging 
was used to determine the ratio of FcγRIIIα expression to expression of L32 + GAPDH for each sample. This ratio 
was used to compare FcγRIIIα expression in BMMC treated with IL-3 + IL-4 to those cultured in IL-3 alone. Data 
are means and standard errors from 3 to 11 samples from five independent experiments. 
 
 
Fig. 4. IL-4 enhances FcγRIII expression without altering protein stability or trafficking. (A) BMMC derived from 
FcγRIIbα−/− mice were cultured in the indicated cytokines for 3 days, and assessed for total FcγRIIIα expression by 
intracellular staining with FITC-2.4G2, as described in Materials and methods. Statistical significance was evaluated 
as described in Fig. 1. *p<0.05 as determined by ANOVA and LSD analysis. (B) BMMC derived from 
FcγRIIb−/− mice were cultured for three days in IL-3 alone or in IL-3 + IL-4 prior to the addition 
of cycloheximide (4 μg/ml final) for the times indicated. Intracellular staining with 2.4G2 was used to assess total 
FcγRIIIα expression. Percent change in expression was determined by comparing mean fluorescence intensities of 
cells treated with cycloheximide to those in DMSO. Data shown are means and standard errors of nine different 
BMMC populations from three representative experiments. (C). BMMC derived from FcγRIIb−/− mice were cultured 
for three days in IL-3 alone or in IL-3 + IL-4 prior to the addition of Brefeldin A (3 μg/ml) for 20 h. Staining with 
2.4G2 was used to assess surface FcγRIII expression by flow cytometry. Percent inhibition was determined by 
comparing mean fluorescence intensities of cells treated with BFA to those treated with media alone. Data shown 
are means and standard errors of six different cell populations in three independent experiments. 
 
To determine if the increase in FcγRIIIα protein expression was related to changes in protein 
stability, we employed the translational inhibitor cycloheximide. FcγRIIb-deficient BMMC were 
stimulated for 3 days with IL-3 alone or with IL-3 + IL-4, after which cycloheximide was added 
to the cultures. Intracellular 2.4G2 staining during the proceeding 24 h showed that the rate of 
total FcγRIIIα degradation was unaltered by IL-4 treatment, indicating that IL-4 stimulation had 
no effect on FcγRIIIα stability (Fig. 4B). 
 
There remained the possibility that IL-4 facilitated recycling of endocytosed FcγRIII, resulting in 
increased surface expression. Brefeldin A (BFA) prevents surface expression of newly 
synthesized proteins by inhibiting transport from the endoplasmic reticulum to the golgi, and 
blocks surface protein recycling by preventing endosomes from fusing with the trans-golgi [26], 
[27]. In order to determine if IL-4 upregulated FcγRIII surface expression by altering protein 
transport or recycling, we assessed changes in surface levels of FcγRIII after the addition of BFA 
to the culture. FcγRIIb-deficient BMMC were cultured in IL-3 alone or IL-3 + IL-4 for 3 days 
prior to the addition of BFA. Surface FcγRIII expression was measured 20 h later, the latest time 
point possible without affecting cell viability. Cells cultured in IL-3 + IL-4 had virtually the 
same sensitivity to BFA as cells cultured in IL-3 alone, as both groups demonstrated a 25% 
reduction in FcγRIII surface expression compared to cells treated with vehicle alone (Fig. 4C). 
These data agree with an earlier study by Kubo and co-workers [28] showing that surface 
FcγRIII is very stable and undergoes little receptor recycling. 
 
Collectively these data argue that IL-4 enhances FcγRIIIα protein expression by increasing 
FcγRIIIα protein synthesis, without altering FcγRIIIα mRNA levels, protein stability or surface 
protein recycling. One possible mechanism by which this could occur is through enhancing 
translational efficiency. IL-4 signaling may regulate mRNA binding proteins, leading to 
increased translation without altering mRNA levels. Identifying these binding proteins, while an 
issue of clear interest, will require significant efforts and is the focus of future study. 
 
The ability of IL-4 to enhance FcγRIII expression is an interesting contrast to IL-4-mediated 
downregulation of FcεRI. Although these events may have opposing effects on mast cell 
function, reduced FcεRI expression may be related to the increase in FcγRIII. Our recent study 
demonstrated that IL-4 diminishes FcεRI expression by decreasing FcεRIβ protein expression 
without affecting FcεRIα or FcRγ (Gillespie et al., submitted). Since FcγRIII expression requires 
pairing with FcεRIγ but not FcεRIβ, it is possible that loss of FcεRIβ Results in a de facto 
increase in FcγRIII expression due to reduced competition for the obligatory γ chain. This theory 
is supported by the demonstration that FcεRIα-deficient mast cells exhibit increased FcγRIII 
expression [16]. Further, these changes would likely be mast cell-specific, explaining the 
differences between our study and those of Te Velde et al., and Pricop et al. [29], [30] who found 
that IL-4 inhibits FcγRIII expression on monocytes. Therefore IL-4 may be enhancing surface 
FcγRIII expression both by increasing FcγRIIIα protein synthesis and limiting competition for its 
expression partner, FcεRIγ. 
 
2.3. The role of Stat6 in IL-4-mediated FcγRIII expression 
 
Because of the importance of Stat6 in IL-4 signaling, we explored the role of Stat6 in IL-4 
mediated FcγRIII upregulation. In order to determine if Stat6 was sufficient to upregulate 
FcγRIII, we infected FcγRIIb-deficient BMMC with a bicistronic retroviral expression 
vector encoding green fluorescence protein (GFP) alone or GFP and a constitutively active 
mutant of Stat6, termed Stat6VT [31], [32]. These cells were maintained in IL-3 alone and 
assessed for FcγRIII expression 5 days post-infection. As shown in Fig. 5, Stat6VT increased 
FcγRIII approximately surface expression 2-fold, closely matching IL-4-mediated upregulation 
(Fig. 1C). These data demonstrate that Stat6 activation alone is sufficient to increase FcγRIII 
expression, data in keeping with IL-4-mediated regulation of FcεRI [, (Gillespie et al., 
submitted)]. Since FcγRIII expression is enhanced without altering FcγRIIIα transcription, it 
would appear that Stat6-mediated effects are indirect, perhaps by regulating expression of RNA 
binding proteins as previously suggested. 
 
 
Fig. 5. Stat6 activation is sufficient to enhance FcγRIII expression. (A) BMMC derived from FcγRIIb−/− mice were 
transfected with bi-cistronic retrovirus expressing GFP alone (control) or GFP and constituitively active Stat6VT as 
described in Materials and methods. The cells were cultured in IL-3 for 3–5 days and stained with PE-2.4G2 to 
determine surface FcγRIII expression. Histogram shown is from a representative sample of GFP-positive cells. (B) 
Average mean fluorescence intensity and standard errors of six samples assessed as in (A). 
 
2.4. IL-4 increases FcγR-mediated inflammatory function on wild type mast cells 
 
Increasing expression of pro-inflammatory FcγRIII might enhance mast cell responses to IgG-
mediated stimuli, however co-expression of inhibitory FcγRIIb receptors could block these 
signals, preventing mast cell activation. With recent data emphasizing the role of mast cell 
FcγRIII-mediated signaling in inflammatory disease [6], [7], [8], [9], [10], the effect of IL-4 on 
IgG-mediated activation of wild type mast cells has clinical importance. 
 
We assessed the effects of IL-4 stimulation on the immediate phase of mast cell activation by 
measuring FcγR-induced release of β-hexosaminidase, a marker of mast cell degranulation [33]. 
Wild type BMMC expressing both FcγRIIb and FcγRIII were cultured in IL-3 alone or in IL-
3 + IL-4 for 3 days, followed by crosslinkage with anti-FcγRIIb/FcγRIII mAb (2.4G2) and goat 
anti-rat IgG for 60 min. Release of the granule component β-hexosaminidase into culture 
supernatants was then assessed by enzyme assay. Degranulation was measured as percent 
specific release of stimulated cells over unstimulated cells. BMMC cultured in IL-3 alone 
showed no significant β-hexosaminidase release after 2.4G2 crosslinkage, consistent with the 
high level of FcγRIIb expression on these cells [25]. However, BMMC cultured in IL-3 + IL-4 
demonstrated enhanced β-hexosaminidase release after activation (Fig. 6). These data indicate 
that selective upregulation of FcγRIII by IL-4 is functionally significant, leading to increased 
IgG-mediated mast cell degranulation. 
 
 
Fig. 6. IL-4 enhances FcγR-mediated β-hexosaminidase release on wild type BMMC. Wild type BMMC were 
cultured in IL-3 alone or in IL-3 + IL-4 for 3 days. Cells were then stimulated with 2.4G2 and goat anti-rat IgG or 
were left unstimulated, and assessed for β-hexosaminidase release as described in Materials and methods. Percent 
specific release was calculated by subtracting β-hexosaminidase release in non-activated cells from that of FcγR XL-
stimulated cells as described in Materials and methods. Data shown are means and standard errors from a minimum 
of six BMMC populations assessed in a minimum of five independent experiments. *p<0.05 when comparing to IL-
3 alone, as determined by ANOVA followed by LSD analysis. 
 
 
Fig. 7. IL-4 alters FcγR-mediated cytokine production. (A) Wild type BMMC were cultured for 3 days with the IL-3 
or IL-3 + IL-4, followed by FcγR XL as described in Fig. 6. Total RNA was subjected to RPA analysis. Data shown 
are one representative RPA from five independent experiments with similar results using 3–11 independent BMMC 
populations. (B) Summary of changes in TNFα mRNA expression. Pixel intensities from (A) were obtained by 
phosphorimager analysis, and the ratio of cytokine gene expression to the sum of the L32 and 
GAPDH housekeeping gene expression was determined. Data are means and standard errors from 3 to 11 samples 
from 3 to 5 independent experiments. (C) Wild type BMMC were cultured in the indicated cytokines for 3 days, 
then stimulated with FcγR XL for 24 h. TNFα release was measured using ELISA as described in Materials and 
methods. Data shown are means and standard errors from three different BMMC populations assessed in three 
independent experiments. Each sample was done in triplicate. The lower limit of detection was 15.4 pg/ml. for 
TNFα. *p<0.05 when compared to cells cultured in IL-3 alone, using ANOVA and LSD analysis. 
 
While mast cell degranulation is part of the early phase of mast cell activation, cytokine 
production is an indicator of the late phase response, and is a critical component of inflammatory 
infiltration and tissue damage [34]. To determine if IL-4 altered FcγR-mediated cytokine 
production, wild type BMMC were cultured for 3 days in IL-3 alone or IL-3 + IL-4, followed by 
activation with FcγR crosslinkage. TNFα mRNA and protein levels were measured by RPA 
and ELISA, respectively. These experiments showed that IL-4 enhanced both FcγR-mediated 
TNFα mRNA levels and protein secretion (Fig. 7), though this increase was modest in 
comparison to the effects on beta hexosaminidase release. Together with the degranulation 
studies, these results demonstrate that IL-4 stimulation enhances the early and late phases of 
FcγR-mediated pro-inflammatory mediator secretion in mast cells. 
 
The ability of IL-4 to alter FcγR signaling in the context of both pro- and anti-inflammatory IgG 
receptors could be due solely to the selective upregulation of FcγRIII. However, FcγRIIb 
expression is still considerable after IL-4 stimulation. It remains possible that enhanced FcγR-
mediated mast cell activation is due partly to enhanced FcγRIII expression and partly to 
inhibition of FcγRIIb signaling. This is the focus of future studies. 
 
The current study demonstrates that IL-4 upregulates FcγRIII surface expression without 
significantly altering expression of FcγRIIb. IL-4 conveys these changes via alterations in 
FcγRIIIα protein expression without affecting mRNA synthesis, protein stability, or receptor 
recycling. Stat6 activation alone induces FcγRIII upregulation, emphasizing the importance of 
this transcription factor in IL-4-initiated signal transduction. Importantly, modifying the surface 
ratio of FcγRIIb to FcγRIII is functionally significant, allowing for degranulation and cytokine 
production after FcγR crosslinkage. Understanding FcγR regulation could be significant to 
inflammatory disease, as recently demonstrated in a rodent model of multiple sclerosis, where 
selective FcγRIII expression on mast cells altered disease severity [17]. Similarly, there is recent 
evidence that FcγR play an important role in a mouse model of rheumatoid arthritis [3]. 
Manipulation of the FcγRIIb/FcγRIII ratio by cytokines could therefore be important for 
controlling and treating inflammatory disease. 
 
3. Materials and methods 
 
3.1. BMMC cultures 
 
BMMC were maintained as primary, factor-dependent, multi-clonal populations in RPMI 1640 
medium (Life Technologies, Grand Island, NY) supplemented with 10% fetal calf serum (FCS), 
2 mM l-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 1 mM sodium pyruvate, and 
1 mM Hepes (cRPMI; all materials from Biofluids, Rockville, MD), to which was added 20% 
volume/volume WEHI-3 cell-conditioned medium (cRPMI/WEHI). BMMC were cultured from 
bone marrow harvested from femurs of BL6x129 wild type, BL6x129 FcγRIIα-deficient, or 
FcRγ-deficient mice (Taconic Farms, Germantown, NY), and maintained in cRPMI/WEHI. After 
3–4 weeks in culture, these populations were >99% mast cells, as judged by morphology 
and flow cytometry staining for expression of FcεRI, CD13, Kit, FcγRII/FcγRIII, and T1/ST2 
(data not shown). The resulting populations were generally used between weeks 4 and 12. 
 
3.2. Cytokines and reagents 
 
Saponin, cycloheximide, and Brefeldin A were purchased from Sigma Immunochemicals (St. 
Louis, MO). Murine IL-3 and IL-4 were purchased from R&D Systems (Minneapolis, MN). 
2.4G2 (rat anti-mouse FcγRII/RIII), mouse IgE, FITC-conjugated rat anti-mouse CD13, FITC-
conjugated rat anti-mouse Kit, PE-conjugated rat isotype control IgG, and FITC-conjugated rat 
anti-mouse CD4 were purchased from BD PharMingen (San Diego, CA). FITC-conjugated goat 
F(ab′2) anti-rat IgG was purchased from Southern Biotechnology Associates (Birmingham, AL). 
FITC-conjugated rabbit anti-mouse IgG was purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA). FITC-conjugated rat anti-mouse T1/ST2 was purchased from 
Morwell Diagnostics (Switzerland). K9.361 anti-FcγRIIb was the kind gift of Ulrich 
Hammerling (Memorial Sloan Kettering Cancer Center, NY). P-Nitropheno-β-d-acetamido-2-
deoxyglucopyranoside was purchased from Sigma (St. Louis, MO). 
 
3.3. Tissue culture conditions for regulation of BMMC FcγR expression 
 
Cells were washed to remove WEHI-3 CM, and incubated in cRPMI at 37 °C for 4–6 h. Cells 
were plated at 3 × 105 cells/ml, 200 μl/well in 96-well flat-bottom plates. IL-3 was added to 
5 ng/ml, followed by the indicated concentrations of IL-4. Cells were then incubated for the 
indicated times. Every 4 days half of the media and cytokines were replaced. FcγRIIb/RIII levels 
were then determined by flow cytometric analysis. 
 
3.4. Flow cytometric analysis 
 
To detect FcγRIIb expression, wild type BMMC were washed with FACS buffer [phosphate-
buffered saline (PBS)/3%FCS/0.1% sodium azide] in 96-well “V” bottom plates, and 
resuspended in unlabelled K9.361 ascites diluted 1:100, or in FACS buffer alone for 30 min at 
4 °C. Cells were then washed twice with FACS buffer and incubated for 30 min at 4 °C with 
10 μg/ml FITC-rabbit anti-mouse IgG, washed twice, and analyzed in the presence of propidium 
iodide to establish a live cell gate. Flow cytometry was performed using a Becton–Dickinson 
FACScan (Becton–Dickinson, San Jose, CA). In some of these experiments, mouse IgG was 
employed as a control primary antibody in place of FACS buffer alone. This resulted in 
background staining not significantly different than FACS buffer alone. To detect FcγRIII 
expression, FcγRIIb-deficient BMMC were washed with FACS buffer and incubated for 30 min 
at 4 °C with 10 μg/ml FITC-2.4G2, either in the presence of unlabelled 2.4G2 to serve as a 
negative control, or without unlabelled 2.4G2. Cells were then washed twice, and analyzed by 
flow cytometry in the presence of propidium iodide. We also assessed FcγRIIb expression by 
2.4G2 staining of BMMC derived from FcRγ chain-deficient mice, which lack expression of 
FcγRIII. These results recapitulated our observations with K9.361 staining of WT BMMC. The 
percent inhibition of FcγR expression was calculated by comparing mean fluorescent intensities 
(MFI) of populations cultured with IL-3 alone to those cultured with IL-3 and other stimuli using 
the following equation: 
 
{[(MFI of IL-3 cultured BMMC) − (MFI of comparison culture)]/(MFI of IL-3 culture)}×100. 
 
To detect expression of CD13, Kit, and T1/ST2, BMMC were incubated with unlabelled 2.4G2 
ascites for 10 min at 4 °C to block nonspecific binding, followed by FITC-labeled antibodies at 
10 μg/ml for 30 min at 4 °C. Cells were then washed twice and analyzed by flow cytometry in 
the presence of propidium iodide. 
 
3.5. 2.4G2 staining of fixed and permeabilized cells 
 
To detect intracellular FcγRIIIα expression, FcγRIIb deficient BMMC (3 × 105 cells/ml) were 
washed twice with 1× PBS and fixed with 4% paraformaldehyde/PBS for 20 min at room 
temperature. Cells were washed with and resuspended in FACS buffer, then stored overnight at 
4 °C. Cells were then resuspended in 100 μl of staining buffer (PBS, 0.1% BSA, 0.01 M Hepes, 
and 0.5% Saponin) and incubated at room temperature for 10 min, prior to 2.4G2 staining as 
described above. Samples were analyzed by flow cytometry using a forward scatter versus side 
scatter gate. 
 
3.6. RNase protection assay 
 
For each sample, 5 × 106 BMMC (cultured at 5 × 106 cells/ml) were starved for 4 h in cRPMI, 
then stimulated with IL-3 (5 ng/ml) alone or IL-3 + IL-4 (20 ng/ml) for the indicated time points. 
To detect cytokine mRNA expression after 2.4G2 crosslinkage, cells were incubated for 10 min 
with 10 μg/ml 2.4G2 at 4 °C, washed, and incubated with 2.5 μg/ml goat F(ab′2) anti-rat IgG for 
90 min at 37 °C. Total RNA was harvested using TRIzol Reagent (InVitrogen, Carlsbad, CA) 
and subjected to RPA analysis using the RiboQuant System (PharMingen, San Diego, CA). Pixel 
intensity was determined using a Typhoon Phosphorimager 445si System equipped with 
ImageQuant software (Molecular Dynamics, Sunnyvale, CA). 
 
3.7. Retroviral infection 
 
FcγRIIb deficient BMMC cultures were infected with retrovirus expressing a bicistronic 
construct consisting of GFP alone or GFP and the constitutively active Stat6 mutant termed 
Stat6VT as described previously [31], [32]. FcγRIII surface expression was assessed on the GFP-
positive population by flow cytometry analysis using phycoerythrin-coupled 2.4G2 antibody. 
 
3.8. β-Hexosaminidase assay 
 
For each sample, 6 × 104 BMMC were cultured with cytokines for the indicated times as 
described above, then stimulated by 2.4G2 crosslinkage in a volume of 50 μL as described above 
for RPA measurements. The supernatant was collected 60 min after activation at 37 °C and 
stored at −20 °C. The pellet was resuspended in PBS/1% NP40, incubated at 0 °C for 30 min, 
vortexed for 5 min, and clarified by centrifugation at 10,000 rpm for 20 min at 4 °C. β-
Hexosaminidase activity in cellular supernatants and pellets was determined as described 
previously [33]. Percent release was calculated by dividing the amount of β-hexosaminidase 
activity in the supernatant by the sum of β-hexosaminidase activity in the supernatant and pellet. 
Specific release was determined by subtracting the percent release of unstimulated cells from 
cells stimulated by 2.4G2 crosslinkage. Non-specific release averages ranged from 7.9 to 15.11% 
on day 4. 
 
3.9. ELISA 
 
For each sample, 5 × 105 BMMC were cultured for 4 days with the indicated cytokines in 
duplicate wells. Equal numbers of BMMC were then stimulated by 2.4G2 crosslinkage in 200 μL 
cRPMI/IL-3 for 24 h at 37 °C as described above for RPA measurements, with the exception that 
an extra wash step was included following the incubation with goat anti-rat IgG. Cytokine 
release was measured using OptEIA ELISA kits (BD Pharmingen, San Diego, CA). 
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